VertexPharma wants to transform the treatment of pain. An upcoming sciatica clinical trial readout will be pivotal.

Vertex achieved its highest level of activity for fiscal 2024 in the current quarter, reporting an adjusted EBITDA (1) of $11.9 million, surpassing the previous company record by $1.0 million. This ...

Vertex (VERX) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.

Supported by world-class markets data from Dow Jones and FactSet, and partnering with Automated Insights, MarketWatch ...